E. Ambrus
University of Szeged
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by E. Ambrus.
Clinical Nuclear Medicine | 2002
Miklós Papós; Tamás Takács; Lajos Trón; Gyula Farkas; E. Ambrus; Szabolcs Szakáll; J. Lonovics; L. Csernay; László Pávics
Purpose To compare the diagnostic values of different methods for the differentiation of malignant from benign pancreatic lesions. Methods In 22 patients with focal pancreatic lesions, the carbohydrate antigen (CA) 19-9 level was measured; abdominal ultrasound (US), computed tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), and F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) were performed; and the value of these methods were analyzed for their use in cancer diagnosis. Results Malignant lesions were identified in six patients and verified by surgery or clinical follow-up. The CA 19-9 level was elevated in four of the five patients examined (sensitivity, 80%). In all six cases, US and CT revealed hypoechogenic and hypodense areas (sensitivity, 100%). In one patient, ERCP was unsuccessful but yielded true-positive results in three others (sensitivity, 60%). The sensitivity of FDG PET was 100%. Sixteen focal cases of pancreatic disease proved to be benign. The CA 19-9 level was elevated in four of them (specificity, 73%). Hypoechogenic and hypodense areas were evident on US and CT in eight patients. The specificity of CT was 50% (8 of 16 cases). The specificity of US was 47% (7 of 15 cases). The specificity of successful ERCP was 92%. Fourteen negative FDG-PET results were truly negative. In two patients, however, the PET findings proved to be falsely positive (specificity, 88%). Conclusions FDG-PET is an effective tool to differentiate malignant from benign focal pancreatic lesions. In persons with focal pancreatic hypoechogenic or hypodense lesions detected by CT or US and an elevated CA 19-9 level, FDG PET should be the next step in the diagnostic strategy.
The American Journal of Gastroenterology | 2001
Tamás Molnár; Miklós Papós; Csaba Gyulai; E. Ambrus; Lilla Kardos; Ferenc Nagy; András Palkó; László Pávics; J. Lonovics
Clinical value of technetium-99m-HMPAO-labeled leukocyte scintigraphy and spiral computed tomography in active crohns disease
Anticancer Research | 1997
E. Ambrus; Mária Rajtár; Katalin Ormándi; Terez Sera; Anna Tószegi; Jenö Láng; László Pávics; L. Csernay
Nuklearmedizin-nuclear Medicine | 1994
László Pávics; F. Grünwald; P. Barzö; E. Ambrus; C. Menzel; A. Schomburg; L. Borda; Eörs Máté; M. Bodosi; L. Csernay; H. J. Biersack
Nuclear Medicine Review | 1998
Laszlo Pavics; Frank Grünwald; Karl Reichmann; Terez Sera; E. Ambrus; Rolf Horn; Alexander Hartmann; Christian Menzel; L. Csernay; Hans J. Biersack
Orvosi Hetilap | 1998
E. Ambrus; K. Ormándi; Terez Sera; Anna Tószegi; L. Csernay; László Pávics
Orvosi Hetilap | 2002
Miklós Papós; Tamás Takács; László Pávics; Gyula Farkas; E. Ambrus; Szabolcs Szakáll; J. Lonovics; L. Csernay; Lajos Trón
Nuclear Medicine Review | 2004
László Pávics; G. Szekeres; E. Ambrus; Szabolcs Kéri; Zoltán Kovács; Miklós Árgyelán; Balázs Kanyó; L. Csernay; Zoltán Janka
Ideggyogyaszati Szemle-clinical Neuroscience | 2009
Aranka László; E. Ambrus; Erika Vörös; András Svékus; Jenö Kóbor; Edit Bereg; János Palatka; László Pávics
Orvosi Hetilap | 1999
E. Ambrus; G. Szekeres; Szabolcs Kéri; L. Csernay; Zoltán Janka; László Pávics
Collaboration
Dive into the E. Ambrus's collaboration.
